It is 1988, and a quiet revolution is taking place in the pharmaceutical industry. Marketers are displacing scientists as leaders at all the major companies. The new breed of executives is uninterested in curing diseases, but only in 'blockbuster drugs' marketed for lifetime use in the management of fear. The last holdout to the trend is the reputable Rhinebeck Laboratories. This is about to change.